{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/agl-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/agl-stock-analysis/data.json",
 "title": "Agilon Health Inc (AGL) Stock Forecast & Price Target (2026)",
 "description": "agilon health, inc. (AGL) stock: Healthcare, Medical Care Facilities. $1.5B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "agilon health, inc. (AGL)",
 "published": "2026-07-20T09:47:03+00:00",
 "modified": "2026-09-16T06:55:53.936+00:00",
 "generated": "2026-09-16T12:54:07.215Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "AGL",
  "name": "agilon health, Inc.",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Medical Care Facilities",
  "country": "United States",
  "website": "https://www.agilonhealth.com"
 },
 "quote": {
  "price": 92.12,
  "previousClose": 92.38,
  "change": -0.26,
  "changePercent": -0.28,
  "open": 96.25,
  "high": 96.65,
  "low": 90.35,
  "volume": 202600,
  "averageVolume": 168520,
  "marketCap": 1546806265,
  "fiftyTwoWeekHigh": 133.039993,
  "fiftyTwoWeekLow": 7.48,
  "marketOpen": false,
  "asOf": "2026-09-16T06:55:53.000Z"
 },
 "statistics": {
  "pe": -3.8842105263157896,
  "eps": -15.23,
  "dividendYield": 0,
  "beta": 3.037,
  "priceToSales": 0.26077366,
  "priceToBook": 6.7827373,
  "revenueTtm": 5920014848,
  "grossMargin": 0.07167720471010736,
  "returnOnEquity": -0.78942
 },
 "technicals": {
  "rsi": 41.49,
  "macd": -1.66,
  "sma50": 99.59,
  "sma200": 53.85,
  "rsiSignal": "Neutral",
  "trend": "Bullish",
  "pricePosition": "Bearish",
  "macdSignal": "Bearish",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Hold",
  "score": 53,
  "consensus": "Hold",
  "fairValue": 92.12,
  "analystTarget": 115,
  "analystCount": 16,
  "wallStreetConsensus": "Hold",
  "generatedAt": "2026-09-16T06:55:53.000Z",
  "priceAtAnalysis": 92.12,
  "volatility": {
   "daily": 5.84,
   "risk": "volatile"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 91.2,
  "aggressiveEntry": 92.12,
  "stopLoss": 81.66,
  "stopLossPercent": 10.46,
  "targets": [
   93.93,
   95.76,
   98.49
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 41.99,
    "base": 79.71,
    "upside90th": 151.28
   },
   {
    "year": 2028,
    "downside10th": 27.87,
    "base": 68.97,
    "upside90th": 170.69
   },
   {
    "year": 2029,
    "downside10th": 19.67,
    "base": 59.67,
    "upside90th": 181.05
   },
   {
    "year": 2030,
    "downside10th": 14.33,
    "base": 51.63,
    "upside90th": 185.99
   },
   {
    "year": 2031,
    "downside10th": 10.66,
    "base": 44.67,
    "upside90th": 187.21
   },
   {
    "year": 2032,
    "downside10th": 8.04,
    "base": 38.65,
    "upside90th": 185.72
   },
   {
    "year": 2033,
    "downside10th": 6.14,
    "base": 33.44,
    "upside90th": 182.23
   },
   {
    "year": 2034,
    "downside10th": 4.72,
    "base": 28.94,
    "upside90th": 177.26
   },
   {
    "year": 2035,
    "downside10th": 3.66,
    "base": 25.04,
    "upside90th": 171.19
   },
   {
    "year": 2036,
    "downside10th": 2.86,
    "base": 21.66,
    "upside90th": 164.36
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "AGL Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$96.25",
    "Day Range": "$90.35 to $96.65",
    "Prev Close": "$92.38",
    "Volume": "202.6K",
    "52-Week Range": "$7.48 to $133.04",
    "Market Cap": "$1.55B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis On price-to-sales, the yardstick used here in place of P/E, AGL trades at 0.2608x, far below the sector average of 3.70x."
   ]
  },
  {
   "id": "financials",
   "title": "AGL Financial Performance",
   "text": [
    "Analysis: In the last 3 quarters, AGL beat estimates 1 times. However, the stock fell 1 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "AGL Analysis",
   "text": [
    "With an RSI of 41.49, agilon health, inc. (AGL) exhibits neutral momentum, neither overbought nor oversold. The stock is currently trading below its 20-day EMA ($92.27) and its 50-day SMA ($99.59), suggesting near-term weakness, but remains above its 200-day SMA ($53.85), indicating a longer-term uptrend is still intact. MACD is negative at -1.66, reinforcing the current bearish short-term trend. Volume on the latest trading day was 202,600, which is 20.2% above the average volume of 168,520, indicating increased investor interest. Key support levels are not clearly defined by long-term averages due to the stock's trading history, but the 200-day SMA at $53.85 represents a significant long-term floor. Resistance may be found near the 50-day SMA at $99.59.",
    "agilon health, inc. reported an EPS of $2.15 versus an estimate of $0.27 for the quarter ending June 2026, a significant beat that could signal improving operational efficiency.",
    "Insiders have made net purchases totaling $352K with no reported sales, indicating a 'Moderate Buy Signal' and potential confidence in the company's future performance.",
    "Forward estimates indicate a sales growth of -8.00% for the next quarter, suggesting potential headwinds for the company's top line.",
    "The most recent earnings report showed a negative EPS surprise and a subsequent price drop, highlighting ongoing profitability challenges.",
    "The base case for agilon health, inc. (AGL) over the next 6-12 months anticipates a stabilization around its current valuation, contingent on its ability to demonstrate a path to profitability. Analysts project a significant turnaround in EPS for the next fiscal year, reaching $2.06, which could support a move towards the median analyst target price of $115. The company's below-sector-average price-to-sales ratio may also attract value investors if profitability concerns are addressed. Upside catalysts could include better-than-expected earnings reports, particularly if they show sustained positive EPS growth and revenue stabilization, aligning with the 'Next Year' growth estimate of 7.00%. Conversely, failure to improve profitability, continued revenue contraction, or negative earnings surprises could push the stock towards its downside projection of $14.33, as indicated by Monte Carlo simulations. The company's ability to execute its strategy and manage costs will be critical in determining its trajectory."
   ],
   "lists": {
    "ProTips": [
     "Insiders at agilon health, inc. (AGL) have been net buyers, with $352K in purchases, signaling a degree of confidence in the company's future prospects.",
     "The stock is trading below its 50-day SMA, indicating potential near-term weakness, but remains above its 200-day SMA, suggesting the longer-term uptrend is intact.",
     "Given the company's negative EPS and projected near-term revenue contraction, investors should closely monitor upcoming earnings reports for signs of a turnaround in profitability and top-line growth."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Strong EPS Beat in Q2 2026",
     "text": "agilon health, inc. reported an EPS of $2.15 versus an estimate of $0.27 for the quarter ending June 2026, a significant beat that could signal improving operational efficiency.",
     "source": "Earnings Report"
    },
    {
     "type": "Bullish",
     "title": "Insider Net Buying Activity",
     "text": "Insiders have made net purchases totaling $352K with no reported sales, indicating a 'Moderate Buy Signal' and potential confidence in the company's future performance.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Projected Revenue Contraction in Next Quarter",
     "text": "Forward estimates indicate a sales growth of -8.00% for the next quarter, suggesting potential headwinds for the company's top line.",
     "source": "Analyst Estimates"
    },
    {
     "type": "Bearish",
     "title": "Negative EPS Surprise and Price Decline",
     "text": "The most recent earnings report showed a negative EPS surprise and a subsequent price drop, highlighting ongoing profitability challenges.",
     "source": "Earnings Report"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "agilon health, inc. (AGL) presents a challenging valuation profile with a negative EPS of -15.23, making its P/E ratio mathematically negative and thus not comparable to sector averages. Its price-to-sales ratio of 0.26 is significantly lower than the sector median of 3.7, suggesting it is undervalued on a sales basis, but this is overshadowed by its profitability issues. The company's return on equity is a significantly negative -78.94%, indicating severe inefficiency in generating profits from shareholder equity. Despite a low debt-to-equity ratio of 0.15, which is favorable, the company's operating margin of 1.30% and net profit margin of -3.92% highlight significant profitability challenges. While revenue growth was 7.2% in the last reported period, forward estimates suggest a contraction in the next quarter and a negative growth rate for the current year, raising concerns about the company's ability to improve its financial performance.",
    "agilon health, inc. (AGL) demonstrated a significant earnings beat in the quarter to June 2026, reporting an EPS of $2.15 against an estimate of $0.27, a surprise of 696.3%. However, this was followed by a substantial price drop of -19.49%. Prior to that, the quarter to March 2026 also saw a large EPS beat of $2.32 versus an estimate of $0.93, accompanied by a strong price increase of 117.81%. The most recent quarter to August 2026 showed a negative EPS surprise of -30.66% with a price decline of 19%.",
    "The primary risk for agilon health, inc. (AGL) is its persistent unprofitability, evidenced by a negative EPS of -15.23 and a negative profit margin of -3.92%. Additionally, forward revenue estimates indicate a contraction in the next quarter, raising concerns about top-line growth sustainability. The stock's neutral RSI and trading below its 50-day SMA suggest potential for further downside pressure in the short term."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "1.55B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "N/A (Negative EPS)"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "-15.23"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "133.04"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "7.48"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bearish RSI Neutral SMA Cross Bullish Price vs SMA Bearish MACD Bearish Golden Cross in effect with the 50-day SMA ($99.59) above the 200-day SMA ($53.85), price is trading below the 50-day SMA."
   ],
   "facts": {
    "RSI": "Neutral",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bearish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "41.49"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-1.66"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "99.59"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "53.85"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.10",
    "Correlation with Nasdaq 100 (QQQ)": "+0.10",
    "Correlation with Bitcoin (BTC)": "+0.42",
    "Correlation with Gold (XAU)": "+0.11"
   }
  },
  {
   "id": "trade-plans",
   "title": "AGL Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (41.5) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$93.93",
    "TARGET 2": "$95.76",
    "TARGET 3": "$98.49",
    "STOP LOSS": "$81.66"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Limited data: Based on ~2 years of trading history. Patterns may not be statistically significant."
   ],
   "facts": {
    "Average Jan return": "+7.67%",
    "Average Feb return": "-4.70%",
    "Average Mar return": "+7.60%",
    "Average Apr return": "+25.15%",
    "Average May return": "+31.96%",
    "Average Jun return": "+6.02%",
    "Average Jul return": "-1.69%",
    "Average Aug return": "-14.92%",
    "Average Sep return": "-6.13%",
    "Average Oct return": "-14.77%",
    "Average Nov return": "-20.51%",
    "Average Dec return": "+2.80%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "5.84%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in AGL in April 2021 would be worth about $1,189 today, compared with about $18,212 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in AGL today could grow to about $2,352 by 2036 in the base case, with a bull case near $17,842 and a bear case around $310. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "AGL Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $51.63 for AGL by 2030 in the base case, from $92.12 today (0.6x over 4 years). The downside path ends near $14.33. These are outcomes of a Monte Carlo simulation run on AGL's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using AGL's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "AGL simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$41.99",
        "$79.71",
        "$151"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$27.87",
        "$68.97",
        "$171"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$19.67",
        "$59.67",
        "$181"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$14.33",
        "$51.63",
        "$186"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$10.66",
        "$44.67",
        "$187"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$8.04",
        "$38.65",
        "$186"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$6.14",
        "$33.44",
        "$182"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$4.72",
        "$28.94",
        "$177"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$3.66",
        "$25.04",
        "$171"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$2.86",
        "$21.66",
        "$164"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "ELV Elevance Health, Inc. NYSE $419.17 -1.20%",
     "url": "https://clearank.com/stock/elv-stock-analysis/"
    },
    {
     "text": "BSX Boston Scientific Corp. NYSE $43.87 -2.62%",
     "url": "https://clearank.com/stock/boston-scientific-bsx/"
    },
    {
     "text": "ILMN Illumina Inc. NASDAQ $222.36 +6.80%",
     "url": "https://clearank.com/stock/ilmn-stock-analysis/"
    },
    {
     "text": "LLY Eli Lilly and Company NYSE $1,146.56 +0.73%",
     "url": "https://clearank.com/stock/eli-lilly-lly/"
    },
    {
     "text": "A Agilent Technologies, Inc. NYSE $150.27 +2.36%",
     "url": "https://clearank.com/stock/agilent-technologies-a/"
    },
    {
     "text": "CAPR Capricor Therapeutics, Inc. NASDAQ $8.56 -2.84%",
     "url": "https://clearank.com/stock/capr-stock-analysis/"
    },
    {
     "text": "NVO Novo Nordisk A/S Sponsored NYSE $42.53 -2.12%",
     "url": "https://clearank.com/stock/novo-nordisk-nvo/"
    },
    {
     "text": "BDX Becton, Dickinson and Company NYSE $185.92 +1.65%",
     "url": "https://clearank.com/stock/bdx-stock-analysis/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "VUG vs SCHG Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vug-vs-schg/"
    },
    {
     "text": "GILD vs BMY Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/gild-vs-bmy/"
    },
    {
     "text": "VOO vs IVV Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/voo-vs-ivv/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "AGL Insider Trading Analysis",
   "facts": {
    "Bought": "$352.0K",
    "Sold": "None",
    "Insiders": "13",
    "Avg Transaction": "$176.0K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in AGL",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "May 18, 2023",
       "cells": [
        "CD&R INVESTMENT ASSOCIATES IX, LTD. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "94.2M",
        "$2.0B"
       ]
      },
      {
       "label": "Sep 14, 2021",
       "cells": [
        "CD&R INVESTMENT ASSOCIATES IX, LTD. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "17.9M",
        "$518.9M"
       ]
      },
      {
       "label": "Aug 11, 2022",
       "cells": [
        "CD&R INVESTMENT ASSOCIATES IX, LTD. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "11.3M",
        "$276.1M"
       ]
      },
      {
       "label": "Jul 7, 2022",
       "cells": [
        "DESAI VEERAL Officer",
        "Sell",
        "319.1K",
        "$8.0M"
       ]
      },
      {
       "label": "Apr 20, 2022",
       "cells": [
        "DESAI VEERAL Officer",
        "Sell",
        "212.7K",
        "$4.8M"
       ]
      },
      {
       "label": "Sep 14, 2021",
       "cells": [
        "HALKIAS THEODORE Officer",
        "Sell",
        "158.6K",
        "$4.6M"
       ]
      },
      {
       "label": "Sep 14, 2021",
       "cells": [
        "MANSUKANI SHARAD S. Director",
        "Sell",
        "156.3K",
        "$4.5M"
       ]
      },
      {
       "label": "Mar 16, 2022",
       "cells": [
        "DESAI VEERAL Officer",
        "Sell",
        "197.3K",
        "$4.0M"
       ]
      },
      {
       "label": "Nov 4, 2021",
       "cells": [
        "SOBOTKA GLENN Officer",
        "Sell",
        "150.0K",
        "$3.8M"
       ]
      },
      {
       "label": "Sep 14, 2021",
       "cells": [
        "DESAI VEERAL Officer",
        "Sell",
        "121.0K",
        "$3.5M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=agilon+health%2C+inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is agilon health, inc.'s stock price forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, agilon health, inc.'s stock price is projected to be $51.63 in 2030 under base case assumptions, with a downside projection of $14.33 and an upside projection of $185.99. These are statistical outcomes, not guarantees."
  },
  {
   "question": "Is agilon health, inc. stock a buy right now?",
   "answer": "agilon health, inc. (AGL) is currently rated a 'Hold' by Wall Street analysts, with a median price target of $115 suggesting a 24.8% upside. While insiders are net sellers, the company's negative EPS and projected near-term revenue contraction present significant risks."
  },
  {
   "question": "What are the key risks facing agilon health, inc.?",
   "answer": "The main risks include persistent unprofitability, with a negative EPS of -15.23, and projected revenue contraction in the upcoming quarter. The stock's neutral RSI and position below its 50-day SMA also indicate potential short-term weakness."
  },
  {
   "question": "How does agilon health, inc. compare to its sector peers?",
   "answer": "agilon health, inc. (AGL) trades at a price-to-sales ratio of 0.26, significantly below the sector median of 3.7. However, its profitability metrics, including a negative profit margin of -3.92% and a significantly negative return on equity of -78.94%, lag far behind sector averages."
  },
  {
   "question": "What is the recent earnings performance of agilon health, inc.?",
   "answer": "The company reported a significant EPS beat in the quarter to June 2026 ($2.15 actual vs $0.27 estimate), but this was followed by a price drop. Previous quarters also showed earnings beats, but the most recent earnings report indicated a negative EPS surprise and a price decline."
  },
  {
   "question": "What is the outlook for agilon health, inc.'s revenue growth?",
   "answer": "While the company reported 7.2% revenue growth in its last period, forward estimates project a contraction of -8.00% in the next quarter and a -2.00% growth for the current year. However, next year's revenue is projected to grow by 7.00%."
  },
  {
   "question": "Are agilon health, inc. insiders buying or selling stock?",
   "answer": "Insiders at agilon health, inc. (AGL) are net buyers, having purchased $352K worth of stock with no reported sales in recent filings. This 'Moderate Buy Signal' suggests some level of insider confidence."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "ELV",
    "name": "Elevance Health, Inc. NYSE",
    "price": "$419.17",
    "change": "-1.20%",
    "url": "https://clearank.com/stock/elv-stock-analysis/"
   },
   {
    "ticker": "BSX",
    "name": "Boston Scientific Corp. NYSE",
    "price": "$43.87",
    "change": "-2.62%",
    "url": "https://clearank.com/stock/boston-scientific-bsx/"
   },
   {
    "ticker": "ILMN",
    "name": "Illumina Inc. NASDAQ",
    "price": "$222.36",
    "change": "+6.80%",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "LLY",
    "name": "Eli Lilly and Company NYSE",
    "price": "$1,146.56",
    "change": "+0.73%",
    "url": "https://clearank.com/stock/eli-lilly-lly/"
   },
   {
    "ticker": "A",
    "name": "Agilent Technologies, Inc. NYSE",
    "price": "$150.27",
    "change": "+2.36%",
    "url": "https://clearank.com/stock/agilent-technologies-a/"
   },
   {
    "ticker": "CAPR",
    "name": "Capricor Therapeutics, Inc. NASDAQ",
    "price": "$8.56",
    "change": "-2.84%",
    "url": "https://clearank.com/stock/capr-stock-analysis/"
   },
   {
    "ticker": "NVO",
    "name": "Novo Nordisk A/S Sponsored NYSE",
    "price": "$42.53",
    "change": "-2.12%",
    "url": "https://clearank.com/stock/novo-nordisk-nvo/"
   },
   {
    "ticker": "BDX",
    "name": "Becton, Dickinson and Company NYSE",
    "price": "$185.92",
    "change": "+1.65%",
    "url": "https://clearank.com/stock/bdx-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "VUG vs SCHG Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vug-vs-schg/"
   },
   {
    "ticker": "GILD vs BMY Comparison",
    "name": "",
    "url": "https://clearank.com/compare/gild-vs-bmy/"
   },
   {
    "ticker": "VOO vs IVV Comparison",
    "name": "",
    "url": "https://clearank.com/compare/voo-vs-ivv/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "DEO",
    "text": "Diageo plc Sponsored",
    "url": "https://clearank.com/stock/deo-stock-analysis/"
   },
   {
    "ticker": "KMB",
    "text": "Kimberly-Clark Corporation",
    "url": "https://clearank.com/stock/kmb-stock-analysis/"
   },
   {
    "ticker": "IAUM",
    "text": "iShares Gold Trust Micro",
    "url": "https://clearank.com/etf/iaum-etf-analysis/"
   },
   {
    "ticker": "SLVR",
    "text": "Sprott Silver Miners & Physical Silver ETF",
    "url": "https://clearank.com/etf/slvr-etf-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "FPS",
    "text": "↑ 9.50%",
    "url": "https://clearank.com/stock/fps-stock-analysis/"
   },
   {
    "ticker": "QRVO",
    "text": "↑ 9.34%",
    "url": "https://clearank.com/stock/qorvo-qrvo/"
   },
   {
    "ticker": "RAY/USD",
    "text": "↓ 9.20%",
    "url": "https://clearank.com/crypto/raydium-ray-usd/"
   },
   {
    "ticker": "EGLD/USD",
    "text": "↓ 9.14%",
    "url": "https://clearank.com/crypto/egld-usd-crypto-analysis/"
   },
   {
    "ticker": "ARB/USD",
    "text": "↑ 19.42%",
    "url": "https://clearank.com/crypto/arbitrum-arb-usd/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "ABBV",
    "text": "AbbVie",
    "url": "https://clearank.com/stock/abbvie-abbv/"
   },
   {
    "ticker": "ABT",
    "text": "Abbott Laboratories",
    "url": "https://clearank.com/stock/abbott-laboratories-abt/"
   },
   {
    "ticker": "AMGN",
    "text": "Amgen",
    "url": "https://clearank.com/stock/amgen-amgn/"
   },
   {
    "ticker": "BDX",
    "text": "Becton, Dickinson and Company",
    "url": "https://clearank.com/stock/bdx-stock-analysis/"
   },
   {
    "ticker": "HCA",
    "text": "HCA Healthcare",
    "url": "https://clearank.com/stock/hca-healthcare-hca/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/agl-agilon-health-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/agl-agilon-health-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "agilon health (AGL) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/agl-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/agl-stock-analysis/",
        "name": "Agilon Health Inc (AGL) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/agl-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/agl-stock-analysis/",
     "name": "Agilon Health Inc (AGL) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-20T09:47:03+00:00",
     "dateModified": "2026-09-16T06:55:53+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/agl-agilon-health-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/agl-stock-analysis/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/agl-stock-analysis/#richSnippet",
     "headline": "Agilon Health Inc (AGL) Stock Forecast & Price Target (2026)",
     "name": "Agilon Health Inc (AGL) Stock Forecast & Price Target (2026)",
     "description": "agilon health, inc. (AGL) stock: Healthcare, Medical Care Facilities. $1.5B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-07-20T09:47:03+00:00",
     "dateModified": "2026-09-16T06:55:53+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "agilon health, inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "AGL"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "agilon health, Inc. is a healthcare services company focused on supporting primary care physicians in managing senior patients through value-based care arrangements. The company provides a platform that helps physician groups coordinate care, manage total patient health needs, and operate under capi",
      "tickerSymbol": "AGL",
      "sameAs": "https://www.agilonhealth.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/agl-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/agl-agilon-health-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/agl-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is agilon health, inc.'s stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, agilon health, inc.'s stock price is projected to be $51.63 in 2030 under base case assumptions, with a downside projection of $14.33 and an upside projection of $185.99. These are statistical outcomes, not guarantees."
     }
    },
    {
     "@type": "Question",
     "name": "Is agilon health, inc. stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "agilon health, inc. (AGL) is currently rated a 'Hold' by Wall Street analysts, with a median price target of $115 suggesting a 24.8% upside. While insiders have been net buyers, the company's negative EPS and projected near-term revenue contraction present significant risks."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key risks facing agilon health, inc.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The main risks include persistent unprofitability, with a negative EPS of -15.23, and projected revenue contraction in the upcoming quarter. The stock's neutral RSI and position below its 50-day SMA also indicate potential short-term weakness."
     }
    },
    {
     "@type": "Question",
     "name": "How does agilon health, inc. compare to its sector peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "agilon health, inc. (AGL) trades at a price-to-sales ratio of 0.26, significantly below the sector median of 3.7. However, its profitability metrics, including a negative profit margin of -3.92% and a significantly negative return on equity of -78.94%, lag far behind sector averages."
     }
    },
    {
     "@type": "Question",
     "name": "What is the recent earnings performance of agilon health, inc.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The company reported a significant EPS beat in the quarter to June 2026 ($2.15 actual vs $0.27 estimate), but this was followed by a price drop. Previous quarters also showed earnings beats, but the most recent earnings report indicated a negative EPS surprise and a price decline."
     }
    },
    {
     "@type": "Question",
     "name": "What is the outlook for agilon health, inc.'s revenue growth?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "While the company reported 7.2% revenue growth in its last period, forward estimates project a contraction of -8.00% in the next quarter and a -2.00% growth for the current year. However, next year's revenue is projected to grow by 7.00%."
     }
    },
    {
     "@type": "Question",
     "name": "Are agilon health, inc. insiders buying or selling stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insiders at agilon health, inc. (AGL) are net buyers, having purchased $352K worth of stock with no reported sales across 30 transactions. This 'Moderate Buy Signal' suggests some level of insider confidence."
     }
    }
   ]
  }
 ]
}